• SSB signs distribution deal for endonuclease   

News & Views

SSB signs distribution deal for endonuclease  

May 22 2012

Sartorius Stedim Biotech (SSB) has signed a worldwide sales and distribution agreement for c-LEcta’s proprietary Serratia marcescens nuclease for biopharmaceutical applications. The customised endonuclease is available under the product name Denarase through all regular SSB sales channels.
c-LEcta has optimised the production process for Serratia marcescens nuclease using a genetically engineered Bacillus strain to increase enzyme activity yields and remove endotoxins.
“This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance,”said Dr. Uwe Gottschalk, VicePresident of Purification Technologies at Sartorius Stedim Biotech.
“The nuclease is a perfect addition to our current purification product portfolio and supports our strategy as a total
solution provider for the biopharmaceutical industry.”

Dr. Marc Struhalla, Managing Director of c-LEcta added: “The technology developed by
c-LEcta allows us to provide nuclease to our customers in the highest quality. We are convinced that with Sartorius Stedim Biotech, we have found the right sales and distribution partner for the successful worldwide commercialisation of our product.”


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events